ZIVO Bioscience, Inc.

Equities

ZIVO

US98978N3098

Food Processing

Market Closed - OTC Markets 12:46:03 2024-04-19 pm EDT 5-day change 1st Jan Change
8 USD 0.00% Intraday chart for ZIVO Bioscience, Inc. +15.94% +566.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ZIVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study CI
Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens CI
ZIVO Bioscience, Inc. announced that it has received $0.531142 million in funding CI
ZIVO Bioscience, Inc. announced that it expects to receive $0.531142 million in funding CI
ZIVO Bioscience, Inc. announced that it has received $0.308936 million in funding CI
ZIVO Bioscience, Inc. announced that it expects to receive $0.308936 million in funding CI
ZIVO Bioscience, Inc. announced that it has received $0.2 million in funding CI
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from S&P TMI Index CI
ZIVO Bioscience, Inc.(OTCPK:ZIVO) dropped from NASDAQ Composite Index CI
ZIVO Bioscience, Inc. announced that it expects to receive $0.15 million in funding CI
ZIVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Zivo Bioscience Insider Bought Shares Worth $199,600, According to a Recent SEC Filing MT
Zivo Says Trial Results Confirm Efficacy of Non-Antibiotic Product Candidate for Treating Coccidiosis in Broiler Chickens MT
Trial Results Confirm Efficacy of ZIVO Bioscience?s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens CI
ZIVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Zivo Bioscience, Inc. Commences Sales of Its Proprietary Algal Biomass as Human Food CI
Zivo Biosciences to Raise $4 Million From Registered Direct Offering, Concurrent Private Placement; Shares Drop MT
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from Russell 3000E Index CI
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from Russell Microcap Index CI
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from Russell Microcap Growth Index CI
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from Russell 3000E Growth Index CI
Zivo Bioscience, Inc. Announces its GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as Human Food Ingredient CI
ZIVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sector Update: Health Care Stocks Advance Premarket Thursday MT
Chart ZIVO Bioscience, Inc.
More charts
Zivo Bioscience, Inc. is a research and development company. The Company operates in both the biotech and agtech sectors, with an intellectual property portfolio comprised of algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Its product candidates are at different stages of development for different applications. It is developing a product candidate targeting poultry gut health. It is developing products for Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Algal biomass for human consumption, and Biomass for supporting skin health/anti-aging. It is focused on licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal, human and dietary supplement, and medical food manufacturers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8 USD
Average target price
12 USD
Spread / Average Target
+50.00%
Consensus
  1. Stock Market
  2. Equities
  3. ZIVO Stock
  4. News ZIVO Bioscience, Inc.
  5. ZIVO Bioscience Appoints Chairman John Payne as President, Chief Executive